Shopping Cart
- Remove All
- Your shopping cart is currently empty
EDP-305, an orally active, potent, and selective agonist of the farnesoid X receptor (FXR), exhibits EC50 values of 34 nM in chimeric FXR within CHO cells and 8 nM in full-length FXR in HEK cells. Demonstrating a potent and consistent antifibrotic effect, EDP-305 is utilized in research related to primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,230 | 6-8 weeks | |
50 mg | $1,610 | 6-8 weeks | |
100 mg | $2,500 | 6-8 weeks |
Description | EDP-305, an orally active, potent, and selective agonist of the farnesoid X receptor (FXR), exhibits EC50 values of 34 nM in chimeric FXR within CHO cells and 8 nM in full-length FXR in HEK cells. Demonstrating a potent and consistent antifibrotic effect, EDP-305 is utilized in research related to primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH). |
Molecular Weight | 630.92 |
Formula | C36H58N2O5S |
Cas No. | 1933507-63-1 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.